secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2024-01-02T23:59:59+00:00
Accession:  0001326110-24-000003
Event type: debt
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.03, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio secures up to $320M royalty and equity financing from Oberland Capital; $210M funded at close
--------------------------------------------------------------------------------

- $200M non-dilutive royalty financing closed; additional $100M contingent on FDA approval of Anktiva for NMIBC (PDUFA Apr 23, 2024).
- $10M equity private placement at $4.11/share; Oberland gets 5-year option for another $10M.
- Nant Capital $505M notes extended to Dec 2025; conversion option at 75% premium to market.
- Total 2023 capital raised reaches $850M; proceeds to fund commercialization and pipeline.
- Royalty rate: initially 3%-7% of net sales (ex-China); capped at 195% of investment; may step down to 1.5%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000132611024000003/0001326110-24-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000132611024000003/ibrx-20231229.htm
  HTML page:      https://secwatch.observer/filing/0001326110-24-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer